Melanotan II reconstitution calculator
Type in a vial size, the diluent volume you added, and a dose figure — the calculator below converts those three numbers into a concentration, a draw volume, and a syringe reading. It performs the same arithmetic as our tirzepatide and sermorelin calculators. What it cannot do, for Melanotan II specifically, is check that arithmetic against an FDA-approved product's own label, because no such label — or product — exists. Read why below before you use it.
There is no approved product or dosing standard behind this calculator
Melanotan II is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), acting broadly across several melanocortin receptors. It is related to, but chemically distinct from, PT-141 (bremelanotide), the shorter, more receptor-selective peptide derived from it that is the basis of the FDA-approved product Vyleesi — Melanotan II itself has never been the active ingredient in any FDA-approved drug. Its research and use history centers mainly on skin tanning (melanogenesis) and appetite/libido effects, studied since the 1990s. A direct check against DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for "melanotan."
Its compounding status is also unsettled, and moved recently, but it has not gone through the same review as several other peptides on this calculator: Melanotan II sat on FDA's interim Section 503A Category 2 list (bulk substances presenting significant safety risks that pharmacies should not compound) from 2023 until April 15, 2026, when FDA removed it — along with eleven other peptides, including BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax and DSIP/Emideltide — because the nomination behind that listing was withdrawn, effective April 22, 2026. That removal does not make compounding Melanotan II legal; it only lifts the "significant safety risk" flag while further review continues. Unlike those seven peptides, Melanotan II was not reviewed at FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026. FDA has instead said it will consult the committee on Melanotan II — together with injectable GHK-Cu, LL-37, DiHexa and PEG-MGF — at a separate meeting to be held before the end of February 2027. As of this page's last review, that meeting has not yet happened, which puts Melanotan II's compounding review a full step further from resolution than BPC-157's, TB-500's, KPV's, MOTS-c's, Epitalon's or DSIP's: it has not yet had its committee hearing at all.
What the tool below actually does is narrower than that context might suggest: it takes the vial size, diluent volume, and dose you type in and returns the concentration and draw volume that arithmetic implies — nothing more. It cannot confirm that a particular vial is what its label claims, that the dose you enter is appropriate for you, that it is currently legal for a pharmacy to have compounded it, or that the product you drew that number from came from a legitimate source. A correct-looking syringe reading is not evidence that any of those things are true.
Sources: DailyMed structured-product-label search for "melanotan" (zero results), FDA's April 15, 2026 removal of Melanotan II from the interim Section 503A Category 2 bulk drug substances list, and reporting on FDA's announced plan to consult its Pharmacy Compounding Advisory Committee on Melanotan II before the end of February 2027, all independently checked 2026-08-02. View the DailyMed search.
Where to go next
- Compare against the compounds this calculator supports that do have an FDA-approved reference product, on the calculator hub.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.